EU's CHMP snubs Janssen-Cilag's Zeftera appeal
This article was originally published in Scrip
The EU's CHMP has confirmed its negative opinion of Basilea Pharmaceutica's broad-spectrum antibiotic Zeftera (ceftobiprole) for the treatment of complicated skin and soft tissue infections (cSSTI), following an appeal by Janssen-Cilag (Johnson & Johnson), which used to own exclusive worldwide rights to the product.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.